Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Results may arrive in time to share and improve %

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Mar 07, 2021 2:15pm

263 Views

Post# 32739266

RE:RE:RE:RE:Results may arrive in time to share and improve %

The future looks bright indeed! If the current trial demonstrates sensational results and the coming X-ray activation trials work out well then this could well be the future of cancer treatment! Unfortunately, given my age and the amount of time these developments take, it could well be a post-Eoganacht future!

Rumpl3StiltSkin wrote:

CancerSlayer wrote:

Rumpl3StiltSkin wrote: Interesting, maybe 1433/Rutherrin would benefit from this. I do think though that by the time TLT rolls out the Osmium/Iridium PDCs there will be diminishing returns from adding nano particles.

Regarding the x-ray treatment of deep-seated tumors, what is encouraging about our PDCs is that they seem to be "not" as reliant on the presence of scintillating nanoparticles. Other PDCs rely significantly on such nanoparticles to first convert the x-ray energy into the activation energy that's needed by the PDC. As preclinically proven in GBM, TLD-1433 can be "directly" activated by x-ray to kill GBM cancer cells...& able to do it at a 75% kill rate which is quite remarkable. I'm sure the TLT team/Dr. McFarland has been perfecting at a nano level their exisitng organometallic frameworks to maximize cell kill even further, whether or not a nano scintillator is used. JMO.

The future of PDT treatment for deep tumors will be x-ray PDT (XPDT) imo with its deep tissue penetration & the comparatively low radiation doses used. TLT's "proprietary" library of activable PDCs gives us not only a head start on the competition, but should remove much of the competition....& the advantage we now hold in organometallic medicine reaches beyond the boundaries of cancer treatment & PDT. Organometallics/PDCs have the ability to act independently (w/o PDT) against various infectious pathogens (viral & bacterial) as demonstrated by Dr. Coombs & others. It seems we're in the infancy of a new era of medicine/therapeutics & I'm happy to see TLT is taking a major lead. JMHO. Good luck....

Thanks CS,

I think once/IF TLT masters how to use x-rays to activate these PDCs it is game over for Cancer, and other big pharma medical aproaches to cancer.
There wont be any new PDCs to emerge that will act significanty better that Dr. Sherri's Osmium and Irridium compounds. Should keep TLT in the forrefront of cancer treatment for the forseeable future. C'mon Phase 2 NMIBC! Exciting times. ;-)